Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia [clinicaltrials:NCT00037791]

Bio2RDF identifier

NCT00037791

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00037791

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00037791

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Intensive chemotherapy ...... platelet transfusion support.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:c94b9201c9355f760e28d6df22d99379]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:5e43897fb3961a838afa637b0db09971]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:6d349e24c1ef9d336f29edaba71d550f]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:71c087f8ecdce5cba895dc4234ea3257]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:7b0068f5cbad87de4dd793392b7740e7]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:8772c3092ec80ab6d1fe5bd3731e7959]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:a0ed207734bbb97b5357fd732f445cac]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:d19fc33ebf1ac88ac4b5b38c1e261e25]

To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia. [clinicaltrials_resource:f24ecca5cf48172f0b4720b5f79b0141]

completion date [clinicaltrials_vocabulary:completion-date]

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00037791 [clinicaltrials_resource:b66536044f29bd13474efd01edf62368]

enrollment [clinicaltrials_vocabulary:enrollment]

180

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2002-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

(PN-152,243)/PN-196,444 [clinicaltrials_resource:2a249c31f98e89c2df9034c6f17d22ff]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2006-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

link [clinicaltrials_vocabulary:link]

To obtain contact information for a study center near you, click here. [clinicaltrials_resource:bb89d314f2e200888ecee324e58fbf46]

location [clinicaltrials_vocabulary:location]

Pfizer Investigational Site [clinicaltrials_resource:aefe60548f8373f01185f9da6c3d79bd]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00037791

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Safety and Efficacy of (PN-152 ...... Platelet Transfusion Support.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

98-OTPO-005

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Pfizer CT.gov Call Center [clinicaltrials_resource:7340297fe8931ae620f630868e86174a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

source [clinicaltrials_vocabulary:source]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

start date [clinicaltrials_vocabulary:start-date]

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00037791 study design [clinicaltrials_resource:f8d1a6990b585b8445a2c80d3198bcce]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00037791

verification date [clinicaltrials_vocabulary:verification-date]

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00037791

http://www.w3.org/2001/XMLSchema#string

title

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Safety and Efficacy of (PN-152 ...... a [clinicaltrials:NCT00037791]

@en